Castle Biosciences Competitors and Similar CompaniesClear all
Castle Biosciences's competitors and similar companies include Pharma Mar, Biocept, Veracyte and Guardant Health.
 Castle Biosciences Castle Biosciences is a company developing and commercializing diagnostic and prognostic tests for dermatologic cancers. |  Pharma Mar Pharma Mar is a biopharmaceutical company that engages in the discovery and development of marine-derived anticancer drugs. |  Biocept Biocept employs cell separation technology to develop a class of diagnostic assays for the early detection and diagnosis of cancer. |  Veracyte Veracyte (formerly known as Calderome) is a genomic diagnostics company that specializes in molecular testing for the treatment of cancer. |  Guardant Health Guardant Health is a company that specializes in non-invasive cancer diagnostics and comprehensive genomic liquid biopsy. | |
Founding Date | Founding Date 2008 | Founding Date 1986 | Founding Date 1993 | Founding Date 2008 | Founding Date 2012 |
Type | Type Public | Type Public | Type Public | Type Public | Type Public |
Tags | |||||
Locations | Locations Friendswood, US HQ Phoenix, US | Locations Colmenar Viejo, ES HQ Madrid, ES | Locations San Diego, US HQ | Locations South San Francisco, US HQ Marseille, FR Haifa, IL Austin, US San Diego, US | Locations Redwood City, US HQ |
Employees | Employees 61013% increase | Employees 500 | Employees 878% decrease | Employees 8154% increase | Employees 1,7681% decrease |
Valuation ($) | Valuation ($) 936.9 m | Valuation ($) 1.4 b | Valuation ($) N/A | Valuation ($) 2.6 b | Valuation ($) 2.7 b |
Financial | |||||
Revenue (est.) | Revenue (est.) $344.2m (FY, 2025) | Revenue (est.) €221.4m (FY, 2025) | Revenue (est.) $25.9m (FY, 2022) | Revenue (est.) $517.1m (FY, 2025) | Revenue (est.) $982m (FY, 2025) |
Cost of goods | Cost of goods $71m (FY, 2025) | Cost of goods €12.3m (FY, 2025) | Cost of goods $28.4m (FY, 2022) | Cost of goods N/A | Cost of goods $349m (FY, 2025) |
Gross profit | Gross profit $273.2m (FY, 2025) | Gross profit €232m (FY, 2025) | Gross profit ($2.5m) (FY, 2022) | Gross profit $362.5m (FY, 2025) | Gross profit $633m (FY, 2025) |
Net income | Net income ($24.2m) (FY, 2025) | Net income €75m (FY, 2025) | Net income ($32.1m) (FY, 2022) | Net income $66.4m (FY, 2025) | Net income ($416.3m) (FY, 2025) |
Funding | |||||
Total funding raised | Total funding raised $ 46.5m | Total funding raised N/A | Total funding raised $ 15.9m | Total funding raised $ 116.3m | Total funding raised $ 550m |
For sources of this data, please see the company profile
View Company Profiles
Pharma Mar
HQ
Colmenar Viejo, ES
Employees
500
Pharma Mar is a biopharmaceutical company that engages in the discovery and development of marine-derived anticancer drugs.
View companyBiocept
HQ
San Diego, US
Employees
87↓ 8% decrease
Biocept employs cell separation technology to develop a class of diagnostic assays for the early detection and diagnosis of cancer.
View companyVeracyte
HQ
South San Francisco, US
Employees
815↑ 4% increase
Veracyte (formerly known as Calderome) is a genomic diagnostics company that specializes in molecular testing for the treatment of cancer.
View companyGuardant Health
HQ
Redwood City, US
Employees
1,768↓ 1% decrease
Guardant Health is a company that specializes in non-invasive cancer diagnostics and comprehensive genomic liquid biopsy.
View company